The Harvard spinout has increased a round already backed by Cedars-Sinai and LabCorp from $28m to $45m following an extension provided by unnamed new investors.
Emulate, a US-based biotechnology spinout of Harvard University, raised $17m on Thursday to close a series B round backed by hospital Cedars-Sinai Medical Center and clinical laboratory network operator LabCorp at $45m.
The fresh funding was provided by unnamed institutional and non-institutional funds as well as private investors. Emulate previously secured $28m in series B capital in March 2016 from backers including Cedars-Sinai.
LabCorp also participated in the first tranche, though at the time it was only…
